Medtronic gets worldwide rights to bone generating protein
This article was originally published in Clinica
Executive Summary
Medtronic Sofamor Danek has obtained worldwide exclusive rights to the recombinant human bone morphogenetic protein rhBMP-2, which was discovered by Wyeth. The new agreement with Wyeth and its licensee, Yamanouchi Pharmaceutical, comes just hours after MSD announced it had obtained rights for Japan and Asia (see Clinica No 1072, p 12). MSD now has global rights to the product in all markets for spinal, orthopaedic and trauma applications.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.